Amoy Diagnostics Co Ltd (300685)

Shenzhen
Currency in CNY
23.94
+0.69(+2.97%)
Closed
300685 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
23.1223.94
52 wk Range
17.2028.79
Key Statistics
Edit
Bid/Ask
23.94 / 23.95
Prev. Close
23.25
Open
23.31
Day's Range
23.12-23.94
52 wk Range
17.2-28.79
Volume
6.79M
Average Volume (3m)
7.39M
1-Year Change
2.35%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
300685 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
31.13
Upside
+30.03%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

Amoy Diagnostics Company Profile

Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on development and commercialization of diagnostics product for oncology in China and internationally. It offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions for evaluating PARP inhibitor-related biomarkers and advancing targeted treatment research in ovarian cancer; AmoyDx HRD complete panel to detect genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel that covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel to detect multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel to detect EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. The company also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel to detect single nucleotide variants, insertions, and deletions within pivotal melanoma tumor genes. In addition, it offers ALK gene fusions and ROS1 gene fusions, multi-gene mutations, EML4-ALK fusion gene, EGFR/ALK/ROS1 mutations, MET mutation, HER2 mutation, RET gene fusions, KRAS mutation, KRAS/NRAS mutations, NRAS mutation, KRAS/NRAS/BRAF mutations, BRAF mutation, PIK3CA five mutations, microsatellite instability, PIK3CA mutation, human papillomavirus genotyping, JAK2 mutation, TERT/HRAS mutations, EGFR 29 mutations, EGFR mutation, ROS1 gene fusions, NTRK gene fusions, BRAF V600 mutations detection kits, as well as DNA and RNA extraction kits under the Super-ARMS and AmoyDx names. The company was founded in 2008 and is based in Xiamen, China.

Employees
1119
Market
China

Compare 300685 to Peers and Sector

Metrics to compare
300685
Peers
Sector
Relationship
P/E Ratio
29.9x18.5x−0.5x
PEG Ratio
0.68−0.030.00
Price/Book
5.2x1.7x2.6x
Price / LTM Sales
8.0x6.0x3.0x
Upside (Analyst Target)
23.3%24.5%56.3%
Fair Value Upside
Unlock28.0%10.0%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 31.13
(+30.03% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.789
Dividend Yield
0.63%
Industry Median 2.03%
Annualised payout
0.15
Paid annually
5-Years Growth
+17.60%
Growth Streak

Earnings

Latest Release
Oct 22, 2024
EPS / Forecast
0.2096 / 0.1758
Revenue / Forecast
305.00M / 304.98M
EPS Revisions
Last 90 days

FAQ

What Is the Amoy Diagnostics (300685) Stock Price Today?

The Amoy Diagnostics stock price today is 23.94.

What Stock Exchange Does Amoy Diagnostics Trade On?

Amoy Diagnostics is listed and trades on the Shenzhen stock exchange.

What Is the Stock Symbol for Amoy Diagnostics?

The stock symbol for Amoy Diagnostics is "300685."

Does Amoy Diagnostics Pay Dividends? What’s The Current Dividend Yield?

The Amoy Diagnostics dividend yield is 0.63%.

What Is the Amoy Diagnostics Market Cap?

As of today, Amoy Diagnostics market cap is 9.43B.

What is Amoy Diagnostics Earnings Per Share?

The Amoy Diagnostics EPS is 0.789.

What Is the Next Amoy Diagnostics Earnings Date?

Amoy Diagnostics will release its next earnings report on 17 Apr 2025.

From a Technical Analysis Perspective, Is 300685 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.